Sutro Biopharma (STRO) Profit After Tax (2017 - 2025)
Historic Profit After Tax for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$56.9 million.
- Sutro Biopharma's Profit After Tax fell 1654.13% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$216.8 million, marking a year-over-year decrease of 7487.84%. This contributed to the annual value of -$227.5 million for FY2024, which is 11299.24% down from last year.
- According to the latest figures from Q3 2025, Sutro Biopharma's Profit After Tax is -$56.9 million, which was down 1654.13% from -$11.5 million recorded in Q2 2025.
- Sutro Biopharma's Profit After Tax's 5-year high stood at $31.1 million during Q4 2023, with a 5-year trough of -$76.0 million in Q1 2025.
- Over the past 5 years, Sutro Biopharma's median Profit After Tax value was -$38.5 million (recorded in 2023), while the average stood at -$37.0 million.
- Per our database at Business Quant, Sutro Biopharma's Profit After Tax soared by 18979.88% in 2023 and then crashed by 33319.81% in 2024.
- Over the past 5 years, Sutro Biopharma's Profit After Tax (Quarter) stood at -$38.1 million in 2021, then increased by 9.26% to -$34.6 million in 2022, then surged by 189.8% to $31.1 million in 2023, then crashed by 333.2% to -$72.4 million in 2024, then rose by 21.51% to -$56.9 million in 2025.
- Its last three reported values are -$56.9 million in Q3 2025, -$11.5 million for Q2 2025, and -$76.0 million during Q1 2025.